| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $3,417,634 ) |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289387 | Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence. | 000 | 2 | NIH | 12/10/2025 | $591,410 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01ES035723 | H3 histone oxidation is a new posttranslational modification linking heavy metal-induced metabolic changes and oncegenic epigenetic reprogramming | 001 | 4 | NIH | 12/8/2025 | $444,350 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 4 | NIH | 12/9/2025 | $480,943 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 3 | NIH | 1/16/2026 | $610,534 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 4 | NIH | 2/10/2026 | $591,443 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 000 | 7 | NIH | 1/22/2026 | $417,038 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA290007 | An integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response | 000 | 2 | NIH | 1/19/2026 | $560,358 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA289581 | Release of interleukin-1a as a mediator of immune evasion in cancer | 000 | 2 | NIH | 12/9/2025 | $511,684 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 3 | NIH | 12/11/2025 | $559,022 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA141244 | Allosteric Regulation of MDMX by Protein Disorder | 000 | 15 | NIH | 12/17/2025 | $304,497 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286417 | Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer | 000 | 2 | NIH | 10/20/2025 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255265 | Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | 000 | 5 | NIH | 1/15/2026 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 2 | NIH | 10/20/2025 | $0 |
| | 2026 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA252042 | Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | 000 | 5 | NIH | 1/12/2026 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA274971 | Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS) | 000 | 3 | NIH | 2/11/2026 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA274489 | Analytical tools for studying the tumor microenvironment leveraging spatial transcriptomics | 000 | 3 | NIH | 1/30/2026 | -$4,751 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA230042 | Investigation of NRF2-Dependent Metabolic Liabilities | 000 | 7 | NIH | 11/19/2025 | -$3,210 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA222215 | Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy | 000 | 7 | NIH | 12/9/2025 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R56CA279060 | Radiomic biomarkers for clinical decision support that predict patient outcomes in serous ovarian carcinoma | 000 | 1 | NIH | 1/16/2026 | -$5,115 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA280367 | Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy | 000 | 2 | NIH | 1/2/2026 | -$6,884 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286226 | Title of Project * L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity | 000 | 1 | NIH | 11/19/2025 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA263575 | Novel Therapy to Inhibit IPMN Progression | 000 | 3 | NIH | 1/29/2026 | -$1,555,827 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA263575 | Novel Therapy to Inhibit IPMN Progression | 000 | 3 | NIH | 1/29/2026 | -$74,401 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA272601 | Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions | 000 | 3 | NIH | 1/2/2026 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA273034 | Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors | 000 | 3 | NIH | 1/2/2026 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241169 | Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment. | 000 | 5 | NIH | 1/14/2026 | $0 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 001 | 1 | NIH | 1/26/2026 | $11,073 |
| | 2026 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 000 | 1 | NIH | 1/26/2026 | -$11,073 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA244100 | Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy | 000 | 4 | NIH | 1/9/2026 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | T32CA233399 | Integrated Program in Cancer and Data Science | 000 | 5 | NIH | 12/2/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21AR081633 | Exploratory Study of T Cell Skin Trafficking and the Role of NKG2D Signaling; Implications in Vitiligo and Melanoma | 000 | 1 | NIH | 12/11/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA282568 | Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach | 000 | 1 | NIH | 1/20/2026 | -$3 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21ES035196 | Novel role of melanin-carbonyls in progression of NRAS mutant melanoma | 000 | 1 | NIH | 11/21/2025 | -$437 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA278603 | Health-related quality of life and patient reported outcomes among people living with HIV and cancer | 000 | 1 | NIH | 11/24/2025 | -$2 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250018 | Functional characterization of prostate cancer risk loci by high throughput sequencing | 000 | 4 | NIH | 11/25/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241559 | Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA236034 | A Stepped-care Psychosocial Intervention for Brain Tumor Family Caregivers | 000 | 5 | NIH | 11/24/2025 | -$3,015 |
| | 2026 | 2023 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | CE152143 | Community Project Funding/Congressionally Directed Spending - Construction | 05 | 1 | HRSA | 12/4/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $55,434,440 ) (Continued on the next page) |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 2 | NIH | 12/12/2024 | $541,074 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U54CA274507 | The Delta Ecology of NSCLC Treatment | 001 | 3 | NIH | 9/11/2025 | $2,097,825 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U54CA274507 | The Delta Ecology of NSCLC Treatment | 002 | 3 | NIH | 9/17/2025 | $67,476 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 2 | NIH | 11/14/2024 | $84,250 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 000 | 2 | NIH | 5/12/2025 | $553,041 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 2 | NIH | 1/14/2025 | $572,062 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 001 | 2 | NIH | 6/4/2025 | $63,562 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA302303 | Trends and outcomes of lung cancer screening among people with and without HIV in the US | 000 | 1 | NIH | 9/23/2025 | $2,991,283 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 002 | 4 | NIH | 9/23/2025 | $141,464 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 001 | 4 | NIH | 9/22/2025 | $146,655 |
|
